News

MedPage Today on MSN23h
Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line
Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...
Healio17h
Vepdegestrant may benefit certain patients with advanced breast cancer with ESR1 mutation
Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...
MedPage Today on MSN23h
Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS
CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...
Healio22h
Assay predicts adjuvant chemotherapy benefit in early-stage non-small cell lung cancer
A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...